Journey Medical (DERM) Competitors $7.12 -0.05 (-0.63%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DERM vs. GYRE, DAWN, VIR, AVXL, ABUS, EOLS, KALV, ANAB, COGT, and ABCLShould you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), Evolus (EOLS), KalVista Pharmaceuticals (KALV), AnaptysBio (ANAB), Cogent Biosciences (COGT), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Journey Medical vs. Gyre Therapeutics Day One Biopharmaceuticals Vir Biotechnology Anavex Life Sciences Arbutus Biopharma Evolus KalVista Pharmaceuticals AnaptysBio Cogent Biosciences AbCellera Biologics Gyre Therapeutics (NASDAQ:GYRE) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Which has more risk and volatility, GYRE or DERM? Gyre Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Do analysts rate GYRE or DERM? Journey Medical has a consensus price target of $9.88, suggesting a potential upside of 38.79%. Given Journey Medical's stronger consensus rating and higher possible upside, analysts plainly believe Journey Medical is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Journey Medical 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do insiders and institutionals hold more shares of GYRE or DERM? 24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 19.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 15.0% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor GYRE or DERM? In the previous week, Gyre Therapeutics had 1 more articles in the media than Journey Medical. MarketBeat recorded 3 mentions for Gyre Therapeutics and 2 mentions for Journey Medical. Gyre Therapeutics' average media sentiment score of 0.70 beat Journey Medical's score of 0.60 indicating that Gyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Journey Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is GYRE or DERM more profitable? Journey Medical has a net margin of -31.74% compared to Gyre Therapeutics' net margin of -84.57%. Gyre Therapeutics' return on equity of -118.43% beat Journey Medical's return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-84.57% -118.43% -71.97% Journey Medical -31.74%-132.10%-26.90% Which has better earnings & valuation, GYRE or DERM? Journey Medical has lower revenue, but higher earnings than Gyre Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$100.64M8.29-$92.93M$0.02445.00Journey Medical$56.24M2.95-$3.85M-$0.39-18.24 Does the MarketBeat Community prefer GYRE or DERM? Journey Medical received 6 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 87.50% of users gave Journey Medical an outperform vote. CompanyUnderperformOutperformGyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesJourney MedicalOutperform Votes787.50% Underperform Votes112.50% SummaryGyre Therapeutics beats Journey Medical on 11 of the 19 factors compared between the two stocks. Get Journey Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DERM vs. The Competition Export to ExcelMetricJourney MedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.80M$6.77B$5.54B$8.63BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-7.578.7427.2420.18Price / Sales2.95261.26420.82164.37Price / Cash28.3765.8538.2534.64Price / Book6.786.677.154.73Net Income-$3.85M$143.26M$3.23B$248.00M7 Day Performance-1.18%10.58%6.39%4.37%1 Month Performance3.42%19.55%15.12%10.75%1 Year Performance26.83%9.06%32.42%15.13% Journey Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DERMJourney Medical2.6907 of 5 stars$7.12-0.6%$9.88+38.8%+52.3%$165.80M$56.24M-7.5790News CoveragePositive NewsGYREGyre Therapeutics0.0973 of 5 stars$7.68-15.3%N/A-23.4%$720.06M$100.64M384.0040High Trading VolumeDAWNDay One Biopharmaceuticals1.5785 of 5 stars$7.01+9.9%$30.57+336.1%-44.6%$710.55M$161.92M-6.8160VIRVir Biotechnology2.931 of 5 stars$5.07+2.6%$32.86+548.1%-51.6%$700.87M$14.30M-1.29580Positive NewsGap UpAVXLAnavex Life Sciences3.8904 of 5 stars$7.56+0.4%$44.00+482.0%+104.9%$645.41MN/A-13.7540Positive NewsABUSArbutus Biopharma2.169 of 5 stars$3.36flat$5.50+63.7%+9.7%$643.53M$6.40M-7.8190Positive NewsEOLSEvolus3.5902 of 5 stars$9.97+8.5%$23.75+138.2%-17.5%$642.83M$275.46M-10.96170High Trading VolumeKALVKalVista Pharmaceuticals4.0353 of 5 stars$12.92+9.5%$24.83+92.2%+26.4%$642.33MN/A-3.55100Positive NewsHigh Trading VolumeANABAnaptysBio1.9558 of 5 stars$21.86-1.7%$40.38+84.7%-1.0%$642.25M$111.87M-3.60100Gap UpCOGTCogent Biosciences1.6087 of 5 stars$5.61+3.1%$14.57+159.7%-17.8%$638.73MN/A-2.2680Positive NewsGap UpHigh Trading VolumeABCLAbCellera Biologics2.9183 of 5 stars$2.14+5.9%$8.33+289.4%-30.7%$638.63M$23.11M-3.51500Positive News Related Companies and Tools Related Companies Gyre Therapeutics Competitors Day One Biopharmaceuticals Competitors Vir Biotechnology Competitors Anavex Life Sciences Competitors Arbutus Biopharma Competitors Evolus Competitors KalVista Pharmaceuticals Competitors AnaptysBio Competitors Cogent Biosciences Competitors AbCellera Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DERM) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredElon’s “Secret Mission”Tesla, SpaceX and Starlink made billions for investors... But a meeting Elon had on March 21st, 2025, could...Behind the Markets | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major shift is coming this July — and Wall Street isn't waiting around. Thanks to a new rule going into e...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Journey Medical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Journey Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DERM Stock Free DERM Stock Alerts